Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GT Biopharma, Inc.GTBP · Entity 7878 | Director | January 27, 2023 | February 01, 2023 |
| ImmunityBio, Inc.IBRX · Entity 3618 | Director | June 09, 2026 | June 11, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Director | June 16, 2020 | June 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GT Biopharma, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2033-01-26 | Direct | 500,000 |
Reported balance
After 2023-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 500,000 · Balance 500,000 F1: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct.
ImmunityBio, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2036-06-09 | Direct | 65,600 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 65,600 · Balance 65,600 F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.
Verastem, Inc.
Report date June 16, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2030-06-16 | Direct | 25,000 |
Reported balance
After 2020-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 00:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 65,600 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001364846-26-000003 · wk-form4_1781136701.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2036-06-09 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:55 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 146,020 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001364846-25-000007 · wk-form4_1765925747.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,020 Underlying: Common Stock · 146,020 shares Expires 2035-12-12 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 11:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-23-003224 · ownership.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:42 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019871 · ownership.xml · derivative · entry 2 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: 1/4th of the shares vest on the date of grant and on each of September 8, 2022, December 8, 2022 and March 8, 2023. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:42 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019871 · ownership.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 Read SEC document |
| February 16, 2021 Filed Oct 7, 2021 18:47 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001654954-21-010887 · section16.xml · derivative · entry 5 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: 1/3rd of the shares vest on February 16, 2021, 2022, and 2023. Read SEC document |
| February 16, 2021 Filed Oct 7, 2021 18:47 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 347,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010887 · section16.xml · nonDerivative · entry 4 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,655 F1 · shares: Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on November 11 2020, 2021 and 2022. Read SEC document |
| December 22, 2020 Filed Oct 7, 2021 18:47 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | PurchaseCommon Stock | 441 | $8.73 | $3,849.93 |
DisclosureSEC source: 0001654954-21-010887 · section16.xml · nonDerivative · entry 3 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,083 Read SEC document |
| December 22, 2020 Filed Oct 7, 2021 18:47 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | PurchaseCommon Stock | 1,374 | $8.87 | $12,187.38 |
DisclosureSEC source: 0001654954-21-010887 · section16.xml · nonDerivative · entry 2 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,642 Read SEC document |
| November 16, 2020 Filed Oct 7, 2021 18:47 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | PurchaseCommon Stock | 3,268 | $3.14 | $10,261.52 |
DisclosureSEC source: 0001654954-21-010887 · section16.xml · nonDerivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,268 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:12 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000904454-20-000411 · edgar.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-19-037503 · a4.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 11, 2018 Filed Feb 13, 2019 21:58 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-19-000227 · edgar.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/11/2018 and ending on 06/11/2019, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:22 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001104659-17-039560 · a4.xml · derivative · entry 1 Wendel Bruce · CIK 0001364846 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.